Published • loading... • Updated
Entera Reports Robust Data for Pipeline Programs in HypoPT and Obesity - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Entera reports robust data for pipeline programs in HypoPT and obesity - BioTuesdays
Entera Bio (NASDAQ: ENTX) has reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its pipeline programs—EB612 in hypoparathyroidism (HypoPT) and EB618 in obesity and metabolic disorders—being co-developed with OPKO Health (NASDAQ: OPK). In a poster presentation, among other data Entera highlighted: EB612 produced robust bioavailability and sustained increases in calcium across three preclinical models; and EB…
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and
·Mount Carroll, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
